Soliton (SOLY) 10-Q 12 Nov 20 2020 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2020	Nov. 03, 2020
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2020
Document Transition Report	false
Entity File Number	001-38815
Entity Registrant Name	Soliton, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	36-4729076
Entity Address, Address Line One	5304 Ashbrook Drive
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77081
City Area Code	844
Local Phone Number	705-4866
Title of 12(b) Security	Common Stock
Trading Symbol	SOLY
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		21,189,943
Entity Central Index Key	0001548187
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 34,626	$ 11,876
Restricted cash	200	200
Total cash	34,826	12,076
Inventory	266	0
Prepaid expenses and other current assets	314	96
Total current assets	35,406	12,172
Property and equipment, net of accumulated depreciation	1,334	848
Intangible and other assets	129	121
Total assets	36,869	13,141
Current liabilities:
Accounts payable	655	1,338
Accrued and other current liabilities	1,690	1,529
Total current liabilities	2,345	2,867
Commitments and contingencies (Note 5)
Stockholders’ equity (deficit):
Common stock	21	17
Additional paid-in capital	100,546	66,300
Accumulated deficit	(66,043)	(56,043)
Total stockholders’ equity	34,524	10,274
Total liabilities and stockholders’ equity	$ 36,869	$ 13,141

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	21,189,943	16,932,184
Common stock shares outstanding (in shares)	21,189,943	16,932,184

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Income Statement [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development	1,256	2,430	3,762	3,660
Sales and marketing	474	34	560	137
Depreciation and amortization	87	73	229	146
General and administrative	1,852	1,764	5,531	5,720
Total operating expenses	3,669	4,301	10,082	9,663
Loss from operations	(3,669)	(4,301)	(10,082)	(9,663)
Other income (expense):
Interest expense	0	0	0	(823)
Interest income	76	6	82	9
Total other income (expense)	76	6	82	(814)
Net loss	(3,593)	(4,295)	(10,000)	(10,477)
Dividend to Series A and B preferred stockholders	0	0	0	(160)
Net loss attributable to common stockholders	$ (3,593)	$ (4,295)	$ (10,000)	$ (10,637)
Net loss per common share, basic and diluted (in dollars per share)	$ (0.17)	$ (0.27)	$ (0.55)	$ (0.83)
Weighted average number of common shares outstanding, basic and diluted (in shares)	21,062,444	15,994,002	18,244,330	12,877,047

Condensed Statements of Changes

Condensed Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Private Investment in Public Equity Offering	Stock Issuance, Excluding PIPE Deal	June 2020 Offering	Preferred StockSeries A Preferred Stock	Preferred StockSeries B Preferred Stock	Common Stock	Common StockPrivate Investment in Public Equity Offering	Common StockStock Issuance, Excluding PIPE Deal	Common StockJune 2020 Offering	Additional Paid-In Capital	Additional Paid-In CapitalPrivate Investment in Public Equity Offering	Additional Paid-In CapitalStock Issuance, Excluding PIPE Deal	Additional Paid-In CapitalJune 2020 Offering	Accumulated Deficit
Balance (in shares) at Dec. 31, 2018					417	2,118	1,998
Balance at Dec. 31, 2018	$ (19,558)				$ 0	$ 2	$ 2				$ 22,569				$ (42,131)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	512										512
Debt discount on convertible notes and notes payable – issuance of warrants	146										146
Payment of deferred direct issuance costs	(186)										(186)
Issuance of common shares for extinguishment of preferred shares (in shares)					(417)	(2,118)
Issuance of common shares for extinguishment of preferred shares					$ 0	$ (2)
Issuance of common shares for extinguishment of preferred shares (in shares)							2,535
Issuance of common shares for extinguishment of preferred shares							$ 2
Issuance of common shares for extinguishment of preferred shares	0
Issuance of common shares for extinguishment of convertible debt (in shares)							6,825
Issuance of common shares for extinguishment of convertible debt	11,785						$ 7				11,778
Issuance of common shares for extinguishment of dividends payable (in shares)							955
Issuance of common shares for extinguishment of dividends payable	4,773						$ 1				4,772
Issuance of common shares (in shares)							2,173
Issuance of common shares	9,874						$ 2				9,872
Issuance of common shares for accelerated vesting (in shares)							127
Issuance of common shares for accelerated vesting	0						$ 0				0
Accrued preferred dividends	(160)														(160)
Net loss	(3,209)														(3,209)
Debt forgiveness	434										434
Balance (in shares) at Mar. 31, 2019							14,613
Balance at Mar. 31, 2019	4,411						$ 14				49,897				(45,500)
Balance (in shares) at Dec. 31, 2018					417	2,118	1,998
Balance at Dec. 31, 2018	(19,558)				$ 0	$ 2	$ 2				22,569				(42,131)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accrued preferred dividends	(160)
Net loss	(10,477)
Debt forgiveness	434
Balance (in shares) at Sep. 30, 2019							16,405
Balance at Sep. 30, 2019	7,182						$ 16				59,934				(52,768)
Balance (in shares) at Mar. 31, 2019							14,613
Balance at Mar. 31, 2019	4,411						$ 14				49,897				(45,500)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	686										686
Issuance of common shares (in shares)								675	406
Issuance of common shares		$ 8,642	$ 0					$ 1	$ 1			$ 8,641	$ (1)
Net loss	(2,973)														(2,973)
Balance (in shares) at Jun. 30, 2019							15,694
Balance at Jun. 30, 2019	10,766						$ 16				59,223				(48,473)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	662										662
Issuance of common shares for extinguishment of convertible debt (in shares)							273
Issuance of common shares for extinguishment of convertible debt	48						$ 0				48
Issuance of common shares (in shares)								0	438
Issuance of common shares		$ 1	$ 0					$ 0	$ 0			$ 1	$ 0
Net loss	(4,295)														(4,295)
Balance (in shares) at Sep. 30, 2019							16,405
Balance at Sep. 30, 2019	7,182						$ 16				59,934				(52,768)
Balance (in shares) at Dec. 31, 2019							16,932
Balance at Dec. 31, 2019	10,274						$ 17				66,300				(56,043)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	711										711
Issuance of common shares (in shares)							11
Net loss	(3,271)														(3,271)
Balance (in shares) at Mar. 31, 2020							16,943
Balance at Mar. 31, 2020	7,714						$ 17				67,011				(59,314)
Balance (in shares) at Dec. 31, 2019							16,932
Balance at Dec. 31, 2019	10,274						$ 17				66,300				(56,043)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accrued preferred dividends	0
Net loss	(10,000)
Debt forgiveness	0
Balance (in shares) at Sep. 30, 2020							21,190
Balance at Sep. 30, 2020	34,524						$ 21				100,546				(66,043)
Balance (in shares) at Mar. 31, 2020							16,943
Balance at Mar. 31, 2020	7,714						$ 17				67,011				(59,314)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	736										736
Issuance of common shares (in shares)							30			4,217
Issuance of common shares				$ 32,046						$ 4				$ 32,042
Net loss	(3,136)														(3,136)
Balance (in shares) at Jun. 30, 2020							21,190
Balance at Jun. 30, 2020	37,360						$ 21				99,789				(62,450)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	757										757
Net loss	(3,593)														(3,593)
Balance (in shares) at Sep. 30, 2020							21,190
Balance at Sep. 30, 2020	$ 34,524						$ 21				$ 100,546				$ (66,043)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,000,000)	$ (10,477,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	209,000	146,000
Stock-based compensation	2,204,000	1,860,000
Write-down of intangible asset	20,000	0
Amortization of debt discount	0	665,000
Changes in operating assets - (increase)/decrease:
Inventory	(266,000)	0
Prepaid expenses and other current assets	(218,000)	(188,000)
Changes in operating liabilities - increase/(decrease):
Accounts payable	(932,000)	(820,000)
Accrued and other current liabilities	161,000	404,000
Non-convertible accrued interest - non-related and related party	0	11,000
Convertible accrued interest - related party	0	146,000
NET CASH USED IN OPERATING ACTIVITIES:	(8,822,000)	(8,253,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for the purchase of property and equipment	(446,000)	(819,000)
Payments for intangibles	(28,000)	(4,000)
NET CASH USED IN INVESTING ACTIVITIES:	(474,000)	(823,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of non-convertible notes payable and accrued interest - related party and non-related party	0	(1,005,000)
Proceeds from issuance of non-convertible notes payable - non-related party	0	300,000
Proceeds from issuance of common shares from IPO, net of costs	0	9,714,000
Proceeds from issuance of common shares from PIPE Offerings, net of costs	0	8,643,000
Proceeds from issuance of common shares from June 2020 Offering, net of costs	32,046,000	0
NET CASH PROVIDED BY FINANCING ACTIVITIES:	32,046,000	17,652,000
Net increase in cash, cash equivalents and restricted cash	22,750,000	8,576,000
Cash, cash equivalents and restricted cash, beginning of period	12,076,000	133,000
Cash, cash equivalents and restricted cash, end of period	34,826,000	8,709,000
Supplemental cash flow disclosures:
Cash paid for interest	0	20,000
Non-cash investing and financing activities:
Additions to property and equipment included in accounts payable	249,000	0
Accrued preferred dividends	0	160,000
Accrued direct issuance costs - offering	0	(277,000)
Capital contributions - debt forgiveness	0	434,000
Issuance of common stock for extinguishment of convertible note payable and accrued interest - related party and non-related party	0	11,833,000
Issuance of common stock for extinguishment of dividends payable	0	4,773,000
Debt discount on convertible notes and notes payable - issuance of warrants	0	146,000
Issuance of common stock for extinguishment of preferred stock A and preferred stock B	$ 0	$ 3,000

Description of the Business, Ba

Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies	Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies Description of the Business Soliton, Inc. (“Soliton” or the “Company”) was organized under the laws of the State of Delaware on March 27, 2012. The Company operates in one segment as a medical device company organized to develop and commercialize products utilizing its proprietary Rapid Acoustic Pulse ("RAP") technology platform. The Company is a pre-revenue stage company with its first products being developed for the removal of tattoos and the reduction of cellulite. The Company received clearance from the U.S. Food & Drug Administration ("FDA") for its tattoo removal indication in June of 2019 and has recently completed a four-site pivotal trial for the reduction of cellulite and filed a 510(k) with the FDA seeking clearance for this indication. The Company is based in Houston, Texas. Upon completion of the development of its products and regulatory clearances to market such products, the Company anticipates revenue will be driven by the sale of its RAP console and disposable cartridges to dermatologists, plastic surgeons and other physician offices, as well as medi-spas under the supervision of a doctor. Basis of Presentation The accompanying condensed interim financial statements are unaudited. These unaudited condensed interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all the information and notes required by generally accepted accounting principles in the United States of America ("GAAP") for complete financial statements. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and accompanying notes as found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 2, 2020. In the opinion of management, the unaudited condensed interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2019 unaudited condensed balance sheet included herein was derived from the audited financial statements, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The Company operates in one reportable segment based on management’s view of its business for purposes of evaluating performance and making operating decisions. The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity related instruments, depreciable lives of long-lived assets (including property and equipment and intangible assets), and the valuation allowance related to deferred taxes. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. The coronavirus disease (“COVID-19”) pandemic has negatively impacted, and may continue to negatively impact, the macroeconomic environment in the United States and globally, including our business, financial condition and results of operations. Due to the evolving and uncertain nature of COVID-19, it is reasonably possible that it could materially impact our estimates, particularly those that require consideration of forecasted financial information, in the near to medium term. These estimates relate to certain accounts including, but not limited to, the valuation allowance related to deferred taxes, intangible assets, and other long-lived assets. The magnitude of the impact will depend on numerous evolving factors that we may not be able to accurately predict, including the duration and extent of the pandemic, the impact of federal, state, local and foreign governmental actions, consumer and provider behavior in response to the pandemic and such governmental actions, and the economic and operating conditions that we may face in the aftermath of COVID-19. On June 30, 2020, the Company completed a public offering ("June 2020 Offering") of 4,216,868 shares of common stock for total gross proceeds of approximately $35.0 million. The shares of Company common stock were sold at a public offering price of $8.30 per share and were purchased by the underwriters from the Company at a price of $7.719 per share. The June 2020 Offering was made under a prospectus supplement and related prospectus filed with the SEC pursuant to the Company’s effective shelf registration statement on Form S-3 (Registration No. 333-236963). Net proceeds from the sale of the common stock on June 30, 2020 was approximately $32.0 million after deducting underwriting discounts and estimated offering expenses. Material Uncertainties The Company is an early stage and emerging growth company and has not generated any revenues to date. As such, the Company is subject to all of the risks associated with early stage and emerging growth companies. Since inception, the Company has incurred losses and negative cash flows from operating activities. For the three and nine months ended September 30, 2020 and 2019, the Company incurred net losses of $3.6 million and $4.3 million, respectively, and $10.0 million and $10.5 million, respectively, and had net cash flows used in operating activities for the nine months ended September 30, 2020 and 2019 of $8.8 million and $8.3 million, respectively. At September 30, 2020, the Company had an accumulated deficit of $66.0 million, working capital of $33.1 million and cash, cash equivalents and restricted cash of $34.8 million. The Company does not expect to experience positive cash flows from operating activities in the near future. The Company expects its cash, cash equivalents and restricted cash on hand of $34.8 million as of September 30, 2020 will be sufficient to fund the Company's operations into the third quarter of 2022 but not beyond. The Company anticipates incurring operating losses for the next few years as it completes the development of its products, seeks requested regulatory clearances to market such products and supports the commercial launch of its products. These factors raise uncertainties about the Company's ability to fund operations in future years. If the Company needs to raise additional capital in order to continue to execute its business plan or a change to its business plan, including obtaining additional regulatory clearance for its products currently under development and commercializing and generating revenues from products under development, there is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital could adversely impact the Company’s ability to achieve its intended business objectives and meet its financial obligations beyond the third quarter of 2022. The accompanying condensed financial statements have been prepared on a going concern basis and do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Inventory Inventory is valued at the lower of cost or net realizable value using the first-in, first-out ("FIFO") method. Inventory consists of raw materials purchased by the Company and held offsite by a vendor. Intangible Assets Intangible assets include trademarks. At September 30, 2020 and December 31, 2019, the Company had trademarks of $0.1 million and $0.1 million, respectively. The Company does not amortize trademarks with indefinite useful lives, rather, such assets are required to be tested for impairment at least annually or sooner if events or changes in circumstances indicate that the asset may be impaired. During the three months ended September 30, 2020, the Company wrote down a trademark with a net book value of $19.7 thousand. Net Loss per Common Share Basic net loss per common share is computed by dividing net loss available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. Unvested restricted stock awards contain dividend rights and are considered participating securities as contemplated for the computations of basic and diluted earnings or loss per share. These securities do not participate in losses and accordingly no such allocation has been made in the periods presented. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2020, potentially dilutive securities included options to purchase 3,409,550 common shares, warrants to purchase 1,324,608 common shares and unvested restricted stock of 120,842 shares. As of September 30, 2019, potentially dilutive securities included options to purchase 2,843,550 common shares, warrants to purchase 888,333 common shares and unvested restricted stock of 170,834 shares. Recent Accounting Standards In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842) ("ASC 842"), which establishes a right-of-use (“ROU”) model requiring a lessee to recognize a ROU asset and a lease liability for all leases with terms greater than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASC 842 was originally effective for fiscal years beginning after December 15, 2019, and interim periods beginning after December 15, 2020 with early adoption permitted. In October 2019, the FASB delayed the implementation of ASC 842 for private companies until fiscal years beginning after December 15, 2020. In June 2020, the FASB further delayed the implementation of ASC 842 for private companies until fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Given the Company's status as an Emerging Growth Company ("EGC"), the Company will adopt ASC 842 in accordance with the private company guidance. The modified retrospective transition approach applies to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company has the option to instead apply the provisions at the effective date without adjusting the comparative periods presented. The Company is currently evaluating the impact of this guidance on its financial position, results of operations, and cash flows. The Company does not believe that any other recently issued effective standards, or standards issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements. Reclassifications

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	9 Months Ended
	Sep. 30, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following ( in thousands ): September 30, December 31, Prepaid insurance $ 207 $ 94 Other prepaids and receivables 107 2 Total prepaid expenses and other current assets $ 314 $ 96 As of September 30, 2020, other prepaids and receivables largely included payments made to vendors for work that has not yet been completed and for payments made as a result of listing requirements for public companies.

Property and Equipment

Property and Equipment	9 Months Ended
	Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and Equipment As of September 30, 2020 and December 31, 2019, the net carrying value of property and equipment was approximately $1.3 million and $0.8 million, respectively, and included $0.7 million and $0, respectively, in construction-in-process for equipment being built and software being developed but not yet placed into service. Depreciation expense for the three months ended September 30, 2020 and 2019 was $0.1 million and $0.1 million, respectively. Depreciation expense for the nine months ended September 30, 2020 and 2019 was $0.2 million and $0.1 million, respectively.

Convertible Notes Payable

Convertible Notes Payable	9 Months Ended
	Sep. 30, 2020
Debt Disclosure [Abstract]
Convertible Notes Payable	Convertible Notes PayableIn connection with the closing of the IPO on February 19, 2019, convertible notes (and related accrued interest) of $11.8 million were converted into 6,825,391 shares of common stock. Certain notes automatically converted, according to their terms, into common stock. Certain holders were not permitted to convert such notes to the extent that the holders or any of its affiliates would beneficially own in excess of 4.99% of the Company’s common stock after such conversion. Due to this limitation, principal representing less than $0.1 million of these notes was later converted into 273,034 shares of the Company's common stock in August and September 2019 when the conversion did not result in the holders and any of its affiliates owning more than 4.99% of the Company's outstanding common shares. All remaining debt instruments were settled at the closing of the IPO.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies On April 5, 2012, the Company entered into a Patent and Technology License Agreement with The University of Texas M.D. Anderson Cancer Center ("MD Anderson"). Pursuant to the agreement, the Company obtained a royalty-bearing, worldwide, exclusive license to intellectual property including patent rights related to the patents and technology the Company uses. Under the agreement, the Company paid a nonrefundable license documentation fee in the high-five digits 30 days after the effective date of the agreement. Additionally, the Company agreed to pay a nonrefundable annual maintenance fee starting on the third anniversary of the effective date of the agreement, which escalates each anniversary and is currently in the mid-five digits. Additionally, the Company agreed to a running royalty percentage of net sales in the mid-single digits. The Company also agreed to make certain milestone payments in the low to mid-six digits and sublicensing payments, including a $0.25 million milestone payment made in June 2019 after the Company received FDA clearance for our RAP device for tattoo removal. The specific patents initially subject to the agreement expire between 2031 and 2032. MD Anderson has the right to terminate the agreement upon advance notice in the event of a default by the Company. The agreement will expire upon the expiration of the licensed intellectual property. The rights obtained by the Company pursuant to the agreement are made subject to the rights of the U.S. government to the extent that the technology covered by the licensed intellectual property was developed under a funding agreement between MD Anderson and the U.S. government. To the extent that is the case, the Company's license agreement with, and the intellectual property rights it has licensed from MD Anderson, are subject to such a funding agreement and any superior rights that the U.S. government may have with respect to the licensed intellectual property. Therefore, there is a risk that the intellectual property rights the Company has licensed from MD Anderson may be non-exclusive or void if a funding agreement related to the licensed technology between MD Anderson and the U.S. government does exist and depending on the terms of such an agreement. Notwithstanding the foregoing, the Company does not believe our RAP technology received any federal funding. All out-of-pocket expenses incurred by MD Anderson in filing, prosecuting and maintaining the licensed patents have been and shall continue to be assumed by the Company. For the nine months ended September 30, 2020 and 2019, the Company paid approximately $0.1 million and $0.1 million, respectively, for expenses related to this agreement. As the inventor of the intellectual property licensed from MD Anderson, Dr. Capelli, the Company's Vice Chairman, Chief Science Officer and Co-Founder, is entitled to 50% of the license income (which is determined after MD Anderson recoups any costs associated therewith) that the Company is required to pay to MD Anderson pursuant to the Company's license agreement with MD Anderson. For the nine months ended September 30, 2020, Dr. Capelli was paid $37.5 thousand from MD Anderson. In addition, Dr. Capelli is entitled to 50% of the proceeds (after the recoupment of any costs associated therewith) from the sale by MD Anderson of 175,000 shares issued to MD Anderson in connection with the license agreement. Purchase Commitments On November 20, 2019, the Company entered into a cooperative development addendum ("Addendum") to its engineering and development services master agreement with Emphysys, Inc. ("Emphysys”). The Addendum states that Emphysys will provide the Company with engineering and design service labor related to shockwave technology for use in dermatology and aesthetics fields for a 36 month period ending July 1, 2022. During the term of the Addendum, the Company agreed to certain minimum annual expenditures. If the Company fails to spend such minimum annual amounts or if the Company terminates the Addendum without cause, the Company will be required to pay Emphysys an early termination fee of no more than $0.4 million. In the event that all or substantially all of the stock or assets of either party are sold then, at the request of the other party, the Addendum may be terminated (without the requirement to pay a termination fee) and the obligation of Emphysys to provide future services to the Company shall terminate. Pursuant to the Addendum, with certain exceptions, Emphysys covenanted that it will not perform or agree to perform services with any company other than Soliton in the area of arc-discharge driven acoustical shockwave generation for medical dermatological or aesthetic dermatological indications during the term of the Addendum or any extension thereof, and for a period of six months after the termination of the Addendum. As of September 30, 2020, the Company had purchase obligations of $2.9 million to Emphysys. This commitment is for services used in the ordinary course of business and does not represent excess commitments or loss contracts. The remaining minimum purchase obligations are $1.3 million and $1.6 million, respectively, for the 12 month periods ending June 30, 2021 and June 30, 2022. If we fail to spend such minimum annual amounts or if the Company terminates the Addendum without cause, the Company will be required to pay Emphysys an early termination fee of no more than $0.4 million. On March 6, 2020, the Company entered into a manufacturing service agreement (the "Agreement") with Sanmina Corporation ("Sanmina"). The Agreement states that Sanmina will provide the Company with certain manufactured products for a one year period, with pricing adjusted for material variations of market prices for components, parts and raw material, including variations resulting from allocations, shortages or tariffs. In addition, pricing will be based on the forecasted volumes provided by the Company and the projected inventory turns as agreed by both parties. Either party may terminate the Agreement or an order under the Agreement for default, if the other party materially breaches the Agreement; provided, however, no termination shall occur until thirty days after the defaulting party is notified in writing of the material breach and has failed to cure or give adequate assurances of performance within the thirty day period after notice of material breach. In addition, the Company may terminate the Agreement for any reason upon thirty days’ prior written notice and may terminate any order under the Agreement for any reason upon 120 days’ (before scheduled shipment) prior written notice. Sanmina may terminate the Agreement for any reason upon ninety days’ notice. In the event the Agreement or an order under the Agreement is terminated for any reason other than a breach by Sanmina, the Company is required to pay Sanmina termination charges equal to (i) the contract price for all finished product existing at the time of termination; (ii) Sanmina’s cost (including labor, components and applicable mark-ups per the pricing model) for all work in process; and (iii) the cost of components ordered by Sanmina pursuant to the Agreement. Lease Commitments The Company leases space for its corporate office, which provides for an original 63 month term beginning on February 1, 2016, with initial rent payments of $7.9 thousand per month that escalate annually to a maximum of $8.9 thousand per month through the expiration of the agreement. On September 15, 2020, the Company entered into a 12 month extension of its corporate office lease. Total rent expense under this office space lease arrangement for each of the three and nine months ended September 30, 2020 and 2019 was $24.2 thousand and $23.6 thousand, respectively, and $0.1 million and $0.1 million, respectively. Future minimum lease payments as of September 30, 2020 were less than $0.2 million through the lease term ending April 30, 2022. Letters of Credit The Company has an irrevocable letter of credit which supports its obligations to pay or perform according to the requirements of an underlying agreement with a certain vendor. Such letter of credit has an initial term of one year, renews automatically for an additional year and can only be modified or canceled with the approval of the beneficiary. As of September 30, 2020, the letter of credit was not used. Legal Proceedings In the normal course of business, from time-to-time, the Company may be subject to claims in legal proceedings. However, the Company does not believe it is currently a party to any pending legal actions. Notwithstanding, legal proceedings are subject to inherent uncertainties and an unfavorable outcome could include monetary damages, and in such event, could result in a material adverse impact on the Company's business, financial position, results of operations or cash flows. Employment Agreements The Company has agreements with certain employees to provide certain benefits in the event of termination where the base salary and certain other benefits would amount to $2.9 million using the rate of compensation in effect at November 2, 2020.

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Stockholders’ Equity (Deficit)	Stockholders’ Equity (Deficit) Adoption of 2018 Stock Plan In June 2018, the Company’s Board of Directors (the "Board") and stockholders adopted the 2018 Stock Plan. The 2018 Stock Plan is designed to enable the Company to offer employees, officers, directors and consultants, as defined, an opportunity to acquire a proprietary interest in the Company. The types of awards that may be granted under the 2018 Stock Plan include stock options, stock appreciation rights, restricted stock, and other stock-based awards subject to limitations under applicable law. All awards are subject to approval by the Company’s Board. The 2018 Stock Plan reserves shares of common stock for issuance in accordance with the 2018 Stock Plan’s terms. Total number of shares reserved and available for issuance under the plan is 4,150,000 shares. As of September 30, 2020, 755,450 shares remained available for grant under the 2018 Stock Plan. Restricted Stock Restricted stock activity for the nine months ended September 30, 2020 is summarized as follows: Number of Weighted- Outstanding, December 31, 2019 158,336 $ 11.54 Vested (37,494) 11.54 Outstanding, September 30, 2020 120,842 $ 11.54 On May 8, 2019, the Company granted and issued 200,000 shares of restricted common stock to three consultants in connection with the provision of services pursuant to agreements entered into in April 2019. The consultants were each accredited investors. 25,000 shares vested within four months of the approval date of the agreement. The remaining 175,000 shares vest over 42 months, beginning on September 19, 2019. As of September 30, 2020, 79,158 shares have vested life-to-date and 120,842 remain unvested. During the three months ended September 30, 2020 and 2019, the Company recorded $0.1 million and $0.2 million, respectively, in stock-based compensation for the restricted shares previously issued. During the nine months ended September 30, 2020 and 2019, the Company recorded $0.4 million and $0.8 million, respectively, in stock-based compensation for the restricted shares previously issued. As of September 30, 2020, there was $1.3 million of unrecognized compensation expense related to restricted shares. Stock Options The following table summarizes stock option activities for the nine months ended September 30, 2020: Number of Weighted Weighted Aggregate Intrinsic Value (i n thousands ) Outstanding, December 31, 2019 2,883,550 $ 2.70 8.62 $ 23,862 Granted 526,000 11.08 — — Outstanding, September 30, 2020 3,409,550 $ 4.00 8.11 $ 12,424 Exercisable, September 30, 2020 1,612,250 $ 2.41 7.84 $ 8,434 During the nine months ended September 30, 2020, the Company granted certain individuals options to purchase 526,000 shares of common stock with an average exercise price of $11.08 per share, with contractual terms ranging from one All options issued and outstanding are being amortized over their respective vesting periods. During the three months ended September 30, 2020 and 2019, the Company recorded option expense of $0.6 million and $0.5 million, respectively. During the nine months ended September 30, 2020 and 2019, the Company recorded option expense of $1.8 million and $1.1 million, respectively. The unrecognized compensation expense for options at September 30, 2020 was $5.8 million. Warrants During the year ended December 31, 2018, the Company issued warrants to purchase 776,350 shares of common stock at an exercise price of $1.75. The warrants expire five years from the date of issuance. The warrants were issued to placement agents and investors in connection with certain notes. In January and February 2019, the Company issued warrants to purchase 300,000 shares of common stock at an exercise price of $1.75 on various dates. The warrants were issued to investors in connection with certain notes. On February 19, 2019, the Company issued warrants to the underwriters of the Company's IPO to purchase 152,081 shares of common stock at an exercise price of $6.00. The warrants expire five years from the date of issuance. The aggregate grant date fair value of these 1,228,431 warrants was $1.6 million, which was determined utilizing the Black-Scholes option pricing model. Variables used in the Black-Scholes option pricing model include (1) discount rates in the range of 2.5% to 2.8% based on the daily yield curve rates for U.S. Treasury obligations, (2) expected terms of five years based on the terms of the warrants, (3) expected volatility of 84.1% to 85.8% based on the historical volatility of comparable companies' stock, (4) no expected dividends, and (5) fair value of the Company's stock at $1.67 per share for warrants issued prior to the IPO, a value determined by the Company's Board after reviewing and considering, among other factors, a valuation report issued by an independent appraisal firm, or the fair value of the Company's stock at the closing of its IPO on February 19, 2019 of $4.87 for warrants on that day. As a result of the Company’s IPO closing on February 19, 2019, $0.7 million of unamortized discount on issuance costs were accelerated and recorded as expense, including $0.1 million for costs associated with convertible notes, $0.1 million for warrants issued in connection with the convertible notes and $0.5 million for warrants issued in connection with non-convertible notes issued prior to the IPO. Warrants issued to underwriters in connection with the IPO were treated as deal costs. PIPE Offerings On June 16, 2019, the Company entered into a private offering with certain institutional and accredited investors for the sale by the Company of 675,000 units (each a “June Unit”) at $14.00 per June Unit for total gross proceeds of $9.5 million. Each June Unit consisted of (i) one share of the Company’s common stock, and (ii) a warrant to purchase 0.7 shares (a total of 472,500) of common stock (each a “June Warrant”) (collectively, "June PIPE"). The June Warrants included in the June Units are exercisable at a price of $16.00 per share commencing on the date of issuance and will expire on August 23, 2024. On July 1, 2019, the Company filed a Registration Statement on Form S-1 to register for resale the common stock underlying the June Units sold with the Company's June 2019 private offering. Net proceeds from the closing of the sale of the June Units on June 19, 2019 were $8.6 million after deducting the placement agent fees and offering expenses. The grant date fair value of these 472,500 June Warrants was $4.4 million, which was determined utilizing the Black-Scholes option pricing model. Variables used in the Black-Scholes option pricing model include (1) discount rate of 1.9% based on the daily yield curve rates for U.S. Treasury obligations, (2) expected term of five years based on the term of the warrants, (3) expected volatility of 84.9% based on the historical volatility of comparable companies' stock, (4) no expected dividends, and (5) fair value of the Company's stock at $14.30 per share. On October 10, 2019, the Company entered into a private offering with certain institutional and accredited investors for the sale by the Company of 485,250 units (each an “October Unit”) at $12.88 per October Unit for total gross proceeds of $6.3 million. Each October Unit consisted of (i) one share of the Company’s common stock and (ii) a warrant to purchase 1.1 shares (a total of 533,775) of common stock (each an “October Warrant”) (collectively, "October PIPE"). The October Warrants included in the October Units are exercisable at a price of $12.88 per share commencing on the date of issuance and will expire on October 10, 2024. On November 8, 2019, the Company filed a Registration Statement on Form S-1 to register for resale the common stock underlying the October Units sold with the Company's October 2019 private offering. Net proceeds from the closing of the sale of the October Units on October 11, 2019 were $5.7 million after deducting the placement agent fees and offering expenses. The grant date fair value of these 533,775 October Warrants was $4.5 million, which was determined utilizing the Black-Scholes option pricing model. Variables used in the Black-Scholes option pricing model include (1) discount rate of 1.6% based on the daily yield curve rates for U.S. Treasury obligations, (2) expected term of five years based on the term of the warrants, (3) expected volatility of 82.9% based on the historical volatility of comparable companies' stock, (4) no expected dividends, and (5) fair value of the Company's stock at $12.88 per share. The fair value amount of the warrants from the two PIPE transactions were included in additional paid-in-capital as deal costs. The following table summarizes warrant activity for the nine months ended September 30, 2020: Number of Weighted Weighted Aggregate Intrinsic Value ( in thousands ) Outstanding, December 31, 2019 1,374,608 $ 10.97 4.43 $ 14 Granted — — — — Exercised (40,891) 1.75 — 247 Forfeited (cashless exercise) (9,109) 1.75 — — Outstanding, September 30, 2020 1,324,608 $ 11.32 3.70 $ — Exercisable, September 30, 2020 1,324,608 $ 11.32 3.70 $ —

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On October 22, 2020, the Board appointed Niquette Hunt as an independent member of the Company’s Board, effective on such date. Ms. Hunt was also appointed to serve on the Board’s audit committee and compensation committee. Ms. Hunt will participate in the Company’s standard compensation program for non-employee directors, including annual cash compensation of $38,000, annual compensation of $9,000 and $6,000 for serving as a member of the audit committee and compensation committee, respectively, and an initial award of a 10 year option to purchase 30,000 shares of the Company's common stock, under the Company's 2018 Stock Plan, with 4 year annual vesting and an exercise price equal to the closing price of the Company's common stock on the date of the appointment. On October 23, 2020, the Board appointed Michael K. Kaminer, M.D., as an independent member of the Company’s Board, effective on such date. Dr. Kaminer was also appointed to serve on the Board’s nominating and governance committee. Dr. Kaminer will participate in the Company’s standard compensation program for non-employee directors, including annual cash compensation of $38,000, annual compensation of $5,000 for serving as a member of the nominating and governance committee and an initial award of a 10 year option to purchase 30,000 shares of the Company's common stock, under the Company's 2018 Stock Plan, with 4 year annual vesting and an exercise price equal to the closing price of the Company's common stock on the date of the appointment. On October 30, 2020, the Company entered into an employment agreement with Brad Hauser to serve as the Company's President and Chief Executive Officer effective November 2, 2020. Mr. Hauser was granted a restricted stock unit award for 200,000 shares of the Company's common stock, under the Company's 2018 Stock Plan, with 4 year annual vesting at a price equal to the closing price of the Company's common stock on the date of the appointment. Mr. Hauser was also granted a 10 year option to purchase 350,000 shares of the Company's common stock, under the Company's 2018 Stock Plan, with a 4 year annual vesting and an exercise price equal to the closing price of the Company's common stock on the date of the appointment. On October 30, 2020, Dr. Chris Capelli transitioned to the position of Chief Science Officer and the Board appointed Mr. Capelli as Vice Chairman of the Board. In connection with Dr. Capelli's transition, the Company entered into an amendment to Dr. Capelli's amended and restated employment agreement.

Description of the Business, _2

Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying condensed interim financial statements are unaudited. These unaudited condensed interim financial statements have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") for interim financial information. Accordingly, they do not include all the information and notes required by generally accepted accounting principles in the United States of America ("GAAP") for complete financial statements. These unaudited condensed interim financial statements should be read in conjunction with the audited financial statements and accompanying notes as found in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 2, 2020. In the opinion of management, the unaudited condensed interim financial statements reflect all the adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position, results of operations and cash flows for the interim periods presented. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. The December 31, 2019 unaudited condensed balance sheet included herein was derived from the audited financial statements, but does not include all disclosures, including notes, required by GAAP for complete financial statements. The Company operates in one reportable segment based on management’s view of its business for purposes of evaluating performance and making operating decisions. The preparation of these unaudited condensed interim financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity related instruments, depreciable lives of long-lived assets (including property and equipment and intangible assets), and the valuation allowance related to deferred taxes. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. The coronavirus disease (“COVID-19”) pandemic has negatively impacted, and may continue to negatively impact, the macroeconomic environment in the United States and globally, including our business, financial condition and results of operations. Due to the evolving and uncertain nature of COVID-19, it is reasonably possible that it could materially impact our estimates, particularly those that require consideration of forecasted financial information, in the near to medium term. These estimates relate to certain accounts including, but not limited to, the valuation allowance related to deferred taxes, intangible assets, and other long-lived assets. The magnitude of the impact will depend on numerous evolving factors that we may not be able to accurately predict, including the duration and extent of the pandemic, the impact of federal, state, local and foreign governmental actions, consumer and provider behavior in response to the pandemic and such governmental actions, and the economic and operating conditions that we may face in the aftermath of COVID-19.
Material Uncertainties	Material Uncertainties The Company is an early stage and emerging growth company and has not generated any revenues to date. As such, the Company is subject to all of the risks associated with early stage and emerging growth companies. Since inception, the Company has incurred losses and negative cash flows from operating activities. For the three and nine months ended September 30, 2020 and 2019, the Company incurred net losses of $3.6 million and $4.3 million, respectively, and $10.0 million and $10.5 million, respectively, and had net cash flows used in operating activities for the nine months ended September 30, 2020 and 2019 of $8.8 million and $8.3 million, respectively. At September 30, 2020, the Company had an accumulated deficit of $66.0 million, working capital of $33.1 million and cash, cash equivalents and restricted cash of $34.8 million. The Company does not expect to experience positive cash flows from operating activities in the near future. The Company expects its cash, cash equivalents and restricted cash on hand of $34.8 million as of September 30, 2020 will be sufficient to fund the Company's operations into the third quarter of 2022 but not beyond. The Company anticipates incurring operating losses for the next few years as it completes the development of its products, seeks requested regulatory clearances to market such products and supports the commercial launch of its products. These factors raise uncertainties about the Company's ability to fund operations in future years. If the Company needs to raise additional capital in order to continue to execute its business plan or a change to its business plan, including obtaining additional regulatory clearance for its products currently under development and commercializing and generating revenues from products under development, there is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital could adversely impact the Company’s ability to achieve its intended business objectives and meet its financial obligations beyond the third quarter of 2022. The accompanying condensed financial statements have been prepared on a going concern basis and do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.
Net Loss per Common Share	Net Loss per Common Share Basic net loss per common share is computed by dividing net loss available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. Unvested restricted stock awards contain dividend rights and are considered participating securities as contemplated for the computations of basic and diluted earnings or loss per share. These securities do not participate in losses and accordingly no such allocation has been made in the periods presented. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. As of September 30, 2020, potentially dilutive securities included options to purchase 3,409,550 common shares, warrants to purchase 1,324,608 common shares and unvested restricted stock of 120,842 shares. As of September 30, 2019, potentially dilutive securities included options to purchase 2,843,550 common shares, warrants to purchase 888,333 common shares and unvested restricted stock of 170,834 shares.
Recent Accounting Standards	Recent Accounting Standards In February 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842) ("ASC 842"), which establishes a right-of-use (“ROU”) model requiring a lessee to recognize a ROU asset and a lease liability for all leases with terms greater than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASC 842 was originally effective for fiscal years beginning after December 15, 2019, and interim periods beginning after December 15, 2020 with early adoption permitted. In October 2019, the FASB delayed the implementation of ASC 842 for private companies until fiscal years beginning after December 15, 2020. In June 2020, the FASB further delayed the implementation of ASC 842 for private companies until fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Given the Company's status as an Emerging Growth Company ("EGC"), the Company will adopt ASC 842 in accordance with the private company guidance. The modified retrospective transition approach applies to leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company has the option to instead apply the provisions at the effective date without adjusting the comparative periods presented. The Company is currently evaluating the impact of this guidance on its financial position, results of operations, and cash flows. The Company does not believe that any other recently issued effective standards, or standards issued but not yet effective, if adopted, would have a material effect on the accompanying financial statements.
Reclassifications	ReclassificationsIn certain instances, amounts reported in prior years' financial statements have been reclassified to conform to the current financial statement presentation. Such reclassifications had an effect on previously reported cash flows between operating and investing activities.

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	9 Months Ended
	Sep. 30, 2020
Prepaid Expense and Other Assets, Current [Abstract]
Summary of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following ( in thousands ): September 30, December 31, Prepaid insurance $ 207 $ 94 Other prepaids and receivables 107 2 Total prepaid expenses and other current assets $ 314 $ 96

Stockholders_ Equity (Deficit)

Stockholders’ Equity (Deficit) (Tables)	9 Months Ended
	Sep. 30, 2020
Equity [Abstract]
Nonvested Restricted Stock Shares Activity	Restricted stock activity for the nine months ended September 30, 2020 is summarized as follows: Number of Weighted- Outstanding, December 31, 2019 158,336 $ 11.54 Vested (37,494) 11.54 Outstanding, September 30, 2020 120,842 $ 11.54
Stock Option Activity	The following table summarizes stock option activities for the nine months ended September 30, 2020: Number of Weighted Weighted Aggregate Intrinsic Value (i n thousands ) Outstanding, December 31, 2019 2,883,550 $ 2.70 8.62 $ 23,862 Granted 526,000 11.08 — — Outstanding, September 30, 2020 3,409,550 $ 4.00 8.11 $ 12,424 Exercisable, September 30, 2020 1,612,250 $ 2.41 7.84 $ 8,434
Warrants Activity	The following table summarizes warrant activity for the nine months ended September 30, 2020: Number of Weighted Weighted Aggregate Intrinsic Value ( in thousands ) Outstanding, December 31, 2019 1,374,608 $ 10.97 4.43 $ 14 Granted — — — — Exercised (40,891) 1.75 — 247 Forfeited (cashless exercise) (9,109) 1.75 — — Outstanding, September 30, 2020 1,324,608 $ 11.32 3.70 $ — Exercisable, September 30, 2020 1,324,608 $ 11.32 3.70 $ —

Description of the Business, _3

Description of the Business, Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 16, 2019USD ($)	Sep. 30, 2020USD ($)	Jun. 30, 2020USD ($)$ / shares	Mar. 31, 2020USD ($)	Sep. 30, 2019USD ($)	Jun. 30, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2020USD ($)segmentshares	Sep. 30, 2019USD ($)shares	Dec. 31, 2019USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of operating segments | segment									1
Number of reportable segments | segment									1
Gross proceeds from issuance of common stock		$ 9,500,000
Net loss			$ (3,593,000)	$ (3,136,000)	$ (3,271,000)	$ (4,295,000)	$ (2,973,000)	$ (3,209,000)	$ (10,000,000)	$ (10,477,000)
Net cash used in operating activities									(8,822,000)	(8,253,000)
Accumulated deficit			(66,043,000)						(66,043,000)		$ (56,043,000)
Working capital			33,100,000						33,100,000
Cash balance			34,800,000						34,800,000
Intangible and other assets			129,000						129,000		$ 121,000
Intangible asset write-off			$ 19,700						$ 20,000	$ 0
Amount of options to purchase (in shares) | shares									3,409,550	2,843,550
Amount of warrants to purchase (in shares) | shares									1,324,608	888,333
Amount of unvested restricted stock (in shares) | shares									120,842	170,834
June 2020 Offering
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Issuance of shares during period, new issues (in shares) | shares	4,216,868
Gross proceeds from issuance of common stock	$ 35,000,000
Offering price (in dollars per share) | $ / shares	$ 8.30			$ 8.30
Purchase price (in dollars per share) | $ / shares	$ 7.719			$ 7.719
Net proceeds from issuance of common stock	$ 32,000,000

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2020	Dec. 31, 2019
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid insurance	$ 207	$ 94
Other prepaids and receivables	107	2
Total prepaid expenses and other current assets	$ 314	$ 96

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Property and equipment, net of accumulated depreciation	$ 1,334	$ 1,334		$ 848
Depreciation expense	100	200	$ 100
Construction in Progress
Property, Plant and Equipment [Line Items]
Property and equipment, net of accumulated depreciation	$ 700	$ 700		$ 0

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Textual) $ in Millions	Feb. 19, 2019USD ($)shares
Debt Disclosure [Abstract]
Convertible notes debt amount | $	$ 11.8
Issuance of common shares for extinguishment of convertible debt (in shares) | shares	6,825,391
Threshold percentage of stock ownership after conversion	4.99%
Convertible debt principal | $	$ 0.1
Convertible number of equity instruments | shares	273,034

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) - USD ($)	Sep. 15, 2020	Feb. 01, 2016	Jun. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Nov. 20, 2019
Other Commitments [Line Items]
Payments for milestones			$ 250,000
Percentage of license income entitlement						50.00%
Penalty payment								$ 400,000
Purchase obligations				$ 2,900,000		$ 2,900,000
Purchase obligation, due June 2021				1,300,000		1,300,000
Purchase obligation, due June 2022				1,600,000		1,600,000
Term of extension	12 months
Future minimum lease payments				200,000		200,000
Postemployment benefits liability				2,900,000		2,900,000
Office Space Lease Arrangement
Other Commitments [Line Items]
Term of contract		63 months
Rent expense				$ 24,200	$ 23,600	100,000	$ 100,000
Office Space Lease Arrangement | Minimum
Other Commitments [Line Items]
Monthly payments for rent		$ 7,900
Office Space Lease Arrangement | Maximum
Other Commitments [Line Items]
Monthly payments for rent		$ 8,900
MD Anderson
Other Commitments [Line Items]
Expenses from transactions with related party						100,000	$ 100,000
Amount owed from related parties						$ 37,500
Issuance of shares during period, new issues (in shares)						175,000

Stockholders_ Equity (Deficit_2

Stockholders’ Equity (Deficit) (Details Textual)	Oct. 10, 2019USD ($)$ / sharesshares	Sep. 19, 2019	Jun. 19, 2019$ / sharesshares	Jun. 16, 2019USD ($)$ / sharesshares	May 08, 2019shares	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)$ / sharesshares	Sep. 30, 2019USD ($)	Sep. 30, 2020USD ($)$ / sharesshares	Dec. 31, 2019$ / sharesshares	Feb. 28, 2019$ / sharesshares	Feb. 19, 2019USD ($)$ / sharesshares	Jan. 31, 2019$ / sharesshares	Dec. 31, 2018$ / sharesshares
Granted (in shares)								526,000
Grants in period, weighted average exercise price (in dollars per share) | $ / shares								$ 11.08
Share price (in dollars per share) | $ / shares													$ 4.87
Number of securities called by warrants (in shares)	533,775												1,228,431
Exercise price of warrants or rights (in dollars per share) | $ / shares						$ 11.32		$ 11.32		$ 11.32	$ 10.97
Term of warrants and rights outstanding	5 years
Warrants outstanding | $	$ 4,500,000												$ 1,600,000
Gross proceeds from issuance of common stock | $				$ 9,500,000
Private Investment in Public Equity Offering
Number of units issued (in shares)	485,250			675,000
Purchase price (in dollars per share) | $ / shares				$ 14
Number of common stock per unit (in shares)	1			1
Proceeds from PIPE Offering | $	$ 5,700,000
Number of warrants per unit (in shares)	1.1		0.7
Convertible Debt | Fifth Note
Unamortized discount remaining | $													700,000
Convertible Notes | Fifth Note
Unamortized discount remaining | $													100,000
Warrants issued with Convertible Notes | Fifth Note
Unamortized discount remaining | $													100,000
Warrants issued with Non-Convertible Notes prior to IPO | Fifth Note
Unamortized discount remaining | $													$ 500,000
Measurement Input, Discount Rate
Warrants outstanding, measurement input	0.016
Measurement Input, Expected Term
Term of warrants and rights outstanding													5 years
Measurement Input, Expected Dividend Payment
Warrants outstanding, measurement input | $ / shares													0
Measurement Input, Share Price
Warrants outstanding, measurement input													1.67
Warrant Issued Under Fourth and Fifth Note
Number of securities called by warrants (in shares)															776,350
Exercise price of warrants or rights (in dollars per share) | $ / shares															$ 1.75
Term of warrants and rights outstanding															5 years
Fifth Note
Number of securities called by warrants (in shares)												300,000		300,000
Exercise price of warrants or rights (in dollars per share) | $ / shares												$ 1.75		$ 1.75
Warrants Issued to Underwriters
Number of securities called by warrants (in shares)													152,081
Exercise price of warrants or rights (in dollars per share) | $ / shares													$ 6
Warrants Issued in Private Investment in Public Equity Offering
Number of securities called by warrants (in shares)				472,500
Exercise price of warrants or rights (in dollars per share) | $ / shares	$ 12.88		$ 16
Warrants outstanding | $				$ 4,400,000
Gross proceeds from issuance of common stock | $	$ 6,300,000
Total proceeds from issuance or sale of equity | $				$ 8,600,000
Warrants Issued in Private Investment in Public Equity Offering | Measurement Input, Discount Rate
Warrants outstanding, measurement input				0.019
Warrants Issued in Private Investment in Public Equity Offering | Measurement Input, Expected Term
Term of warrants and rights outstanding				5 years
Warrants Issued in Private Investment in Public Equity Offering | Measurement Input, Price Volatility
Warrants outstanding, measurement input				0.849
Warrants Issued in Private Investment in Public Equity Offering | Measurement Input, Expected Dividend Payment
Warrants outstanding, measurement input | $ / shares				0
Warrants Issued in Private Investment in Public Equity Offering | Measurement Input, Share Price
Warrants outstanding, measurement input | $ / shares				14.30
Minimum | Measurement Input, Discount Rate
Warrants outstanding, measurement input													0.025
Minimum | Measurement Input, Price Volatility
Warrants outstanding, measurement input	0.829												0.841
Maximum | Measurement Input, Discount Rate
Warrants outstanding, measurement input													0.028
Maximum | Measurement Input, Price Volatility
Warrants outstanding, measurement input													0.858
Restricted Stock
Shares vested in period (in shares)								37,494		79,158
Unvested shares remaining (in shares)						120,842		120,842		120,842	158,336
Stock-based compensation expense | $						$ 100,000	$ 200,000	$ 400,000	$ 800,000
Unamortized expense remaining | $						1,300,000		$ 1,300,000		$ 1,300,000
Restricted Stock | Share-based Payment Arrangement, Tranche One
Shares vested in period (in shares)					25,000
Restricted Stock | Share-based Payment Arrangement, Tranche Two
Shares vested in period (in shares)								175,000
Award vesting period					4 months
Share-based Payment Arrangement, Option
Stock-based compensation expense | $						600,000	$ 500,000	$ 1,800,000	$ 1,100,000
Unamortized expense remaining | $						$ 5,800,000		5,800,000		$ 5,800,000
Aggregate grant date fair value | $								4,200,000
Fair value assumptions, expected dividend payments | $								$ 0
Share-based Payment Arrangement, Option | Minimum
Expiration term period								1 year
Fair value assumptions discount rate								0.10%
Fair value assumptions, expected term								5 years 6 months
Fair value assumptions, expected volatility rate								83.10%
Share price (in dollars per share) | $ / shares						$ 6.44		$ 6.44		$ 6.44
Share-based Payment Arrangement, Option | Maximum
Expiration term period								10 years
Fair value assumptions discount rate								1.60%
Fair value assumptions, expected term								6 years 3 months
Fair value assumptions, expected volatility rate								88.30%
Share price (in dollars per share) | $ / shares						$ 13.50		$ 13.50		$ 13.50
Share-based Payment Arrangement, Option | Share-based Payment Arrangement, Tranche One
Award vesting period		42 months
Share-based Payment Arrangement, Option | Share-based Payment Arrangement, Tranche One | Minimum
Award vesting rights, percentage								8.33%
Share-based Payment Arrangement, Option | Share-based Payment Arrangement, Tranche One | Maximum
Award vesting rights, percentage								25.00%
Share-based Payment Arrangement, Option | Share-based Payment Arrangement, Tranche Two | Minimum
Award vesting period								1 year
Share-based Payment Arrangement, Option | Share-based Payment Arrangement, Tranche Two | Maximum
Award vesting period								4 years
Three Consultants | Restricted Stock
Grants of restricted stock in period (in shares)					200,000
Certain Individuals
Granted (in shares)								526,000
Grants in period, weighted average exercise price (in dollars per share) | $ / shares								$ 11.08
2018 Stock Plan
Common stock, capital shares reserved for future issuance (in shares)						4,150,000		4,150,000		4,150,000
Number of shares remaining (in shares)						755,450		755,450		755,450

Stockholders_ Equity (Deficit_3

Stockholders’ Equity (Deficit) - Restricted Stock (Details) - Restricted Stock - $ / shares	9 Months Ended	17 Months Ended
	Sep. 30, 2020	Sep. 30, 2020
Outstanding (in shares)	158,336
Outstanding (in dollars per share)	$ 11.54
Vested (in shares)	(37,494)	(79,158)
Vested (in dollars per share)	$ 11.54
Outstanding (in shares)	120,842	120,842
Outstanding (in dollars per share)	$ 11.54	$ 11.54

Stockholders_ Equity (Deficit_4

Stockholders’ Equity (Deficit) - Stock Options (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2020	Sep. 30, 2020	Dec. 31, 2019
Equity [Abstract]
Outstanding (in shares)	2,883,550	2,883,550
Granted (in shares)		526,000
Outstanding (in shares)		3,409,550
Exercisable (in shares)		1,612,250
Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 2.70	$ 2.70
Granted (in dollars per share)		11.08
Outstanding, Weighted Average Exercise Price (in dollars per share)		4
Exercisable (in dollars per share)		$ 2.41
Outstanding, Weighted Average Remaining Life (Year)	8 years 7 months 13 days	8 years 1 month 9 days
Exercisable, Weighted Average Remaining Life (Year)		7 years 10 months 2 days
Outstanding, Aggregate Intrinsic Value		$ 12,424	$ 23,862
Exercisable, Aggregate Intrinsic Value		$ 8,434

Stockholders_ Equity (Deficit_5

Stockholders’ Equity (Deficit) - Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Mar. 31, 2020	Sep. 30, 2020
Equity [Abstract]
Warrants Outstanding (in shares)	1,374,608	1,374,608
Warrants Granted (in shares)		0
Warrants Exercised (in shares)		(40,891)
Warrant forfeited (cashless exercise), shares (in shares)		(9,109)
Warrants Outstanding (in shares)		1,324,608
Warrants Exercisable (in shares)		1,324,608
Warrants Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 10.97	$ 10.97
Warrants Granted, Weighted Average Exercise Price (in dollars per share)		0
Warrants Exercised, Weighted Average Exercise Price (in dollars per share)		1.75
Warrants Forfeited (cashless exercise), Weighted Average Exercise Price (in dollars per share)		1.75
Warrants Outstanding, Weighted Average Exercise Price (in dollars per share)		11.32
Warrants Exercisable, Weighted Average Exercise Price (in dollars per share)		$ 11.32
Warrants Outstanding, Weighted Average Remaining Contractual Term (Year)	4 years 5 months 4 days	3 years 8 months 12 days
Warrant Exercisable, Weighted Average Remaining Contractual Term (Year)		3 years 8 months 12 days
Warrants Outstanding, Aggregate Intrinsic Value	$ 14	$ 14
Warrants Exercised, Aggregate Intrinsic Value		247
Warrants Outstanding, Aggregate Intrinsic Value		0
Warrants Exercisable, Aggregate Intrinsic Value		$ 0

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	Oct. 30, 2020	Oct. 23, 2020	Oct. 22, 2020	Sep. 30, 2020
Subsequent Event [Line Items]
Granted (in shares)				526,000
Subsequent Event | Niquette Hunt
Subsequent Event [Line Items]
Annual cash compensation			$ 38,000
Initial award option purchasing term			10 years
Shares purchase option			30,000
Award vesting period			4 years
Subsequent Event | Michael K. Kaminer, M.D.
Subsequent Event [Line Items]
Annual cash compensation		$ 38,000
Initial award option purchasing term		10 years
Shares purchase option		30,000
Award vesting period		4 years
Subsequent Event | Brad Hauser
Subsequent Event [Line Items]
Initial award option purchasing term	10 years
Shares purchase option	350,000
Subsequent Event | Restricted Stock Units (RSUs) [Member] | Brad Hauser
Subsequent Event [Line Items]
Award vesting period	4 years
Granted (in shares)	200,000
Subsequent Event | Member of Audit Committee | Niquette Hunt
Subsequent Event [Line Items]
Annual cash compensation			$ 9,000
Subsequent Event | Member of Compensation Committee | Niquette Hunt
Subsequent Event [Line Items]
Annual cash compensation			$ 6,000
Subsequent Event | Member of Nominating and Governance Committee | Michael K. Kaminer, M.D.
Subsequent Event [Line Items]
Annual cash compensation		$ 5,000